As of April 15, 2025, Novo Nordisk A/S (NOVO-B.CO) has a market cap of $285.97 billion USD. According to our data, Novo Nordisk A/S is ranked No.32 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 15, 2025 | $285.97 B |
-10.02%
|
Dec 30, 2024 | $317.82 B |
-9.59%
|
Dec 29, 2023 | $351.54 B |
50.74%
|
Dec 30, 2022 | $233.21 B |
29.53%
|
Dec 30, 2021 | $180.04 B |
75.62%
|
Dec 30, 2020 | $102.51 B |
12.77%
|
Dec 30, 2019 | $90.90 B |
32.92%
|
Dec 28, 2018 | $68.39 B |
-8.60%
|
Dec 29, 2017 | $74.82 B |
35.35%
|
Dec 30, 2016 | $55.28 B |
-34.55%
|
Dec 30, 2015 | $84.45 B |
55.91%
|
Dec 30, 2014 | $54.17 B |
33.38%
|
Dec 30, 2013 | $40.61 B |
10.55%
|
Dec 28, 2012 | $36.74 B |
41.30%
|
Dec 30, 2011 | $26.00 B |
6.57%
|
Dec 30, 2010 | $24.40 B |
93.29%
|
Dec 30, 2009 | $12.62 B |
24.92%
|
Dec 30, 2008 | $10.11 B |
-17.97%
|
Dec 28, 2007 | $12.32 B |
44.53%
|
Dec 29, 2006 | $8.52 B |
34.90%
|
Dec 30, 2005 | $6.32 B |
-39.81%
|
Dec 31, 2004 | $10.50 B |
26.30%
|
Dec 31, 2003 | $8.31 B |
19.45%
|
Dec 31, 2002 | $6.96 B |
-39.51%
|
Dec 31, 2001 | $11.50 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Eli Lilly
LLY
|
$679.94 B |
-0.022 M
|
![]() USA
|
![]() Sanofi
SNY
|
$123.58 B |
-0.002 M
|
![]() France
|
![]() AstraZeneca
AZN
|
$210.42 B |
-0.005 M
|
![]() UK
|
![]() Bristol-Myers Squibb
BMY
|
$101.74 B |
-0.001 M
|
![]() USA
|
![]() Merck
MRK
|
$197.26 B |
0.003 M
|
![]() USA
|
![]() Pfizer
PFE
|
$127.27 B |
-0.003 M
|
![]() USA
|
![]() GlaxoSmithKline
GSK
|
$72.33 B |
-0.002 M
|
![]() UK
|
![]() Johnson & Johnson
JNJ
|
$370.20 B |
0.003 M
|
![]() USA
|
![]() AbbVie
ABBV
|
$312.76 B |
-0.013 M
|
![]() USA
|
![]() Amgen
AMGN
|
$158.77 B |
0.132 B
|
![]() USA
|
![]() Novo Nordisk
NVO
|
$286.98 B |
70.023 B
|
![]() Denmark
|
![]() Teva Pharmaceutical Industries
TEVA
|
$15.60 B |
0.000 M
|
![]() Israel
|
Market Cap | = | NOVO-B.CO Stock Price | * | NOVO-B.CO Shares Outstanding |
= | $64.42 | * | 3.36 B | |
= | $285.97 B |